Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Thousand Oaks California-based company is expected to report a 96.5% decrease in revenue to $1.398 million from $40.19 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Atara Biotherapeutics Inc is for a loss of 86 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $16.50, about 28.4% above its last closing price of $11.82
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.32 | -0.46 | 0.19 | Beat | 141.3 |
Mar. 31 2025 | -1.96 | -1.98 | 3.50 | Beat | 276.8 |
Dec. 31 2024 | -3.76 | -3.58 | -1.19 | Beat | 66.7 |
Sep. 30 2024 | -2.11 | -1.93 | -2.93 | Missed | -51.6 |
Jun. 30 2024 | -1.38 | -1.56 | -3.10 | Missed | -98.4 |
Mar. 31 2024 | -6.17 | -6.41 | -5.75 | Beat | 10.3 |
Dec. 31 2023 | -7.75 | -12.05 | -14.00 | Missed | -16.2 |
Sep. 30 2023 | -16.57 | -16.55 | -16.50 | Beat | 0.3 |
This summary was machine generated November 7 at 13:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments